These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28201828)

  • 1. Add on Exenatide Treatment is Beneficial in Poorly Controlled Obese Type 2 Diabetics under Intensive Insulin Regimens.
    Sönmez A; Dinç M; Taşlıpınar A; Aydoğdu A; Meriç C; Başaran Y; Haymana C; Demir O; Yılmaz İ; Azal Ö
    Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):256-261. PubMed ID: 28201828
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.
    Viswanathan P; Chaudhuri A; Bhatia R; Al-Atrash F; Mohanty P; Dandona P
    Endocr Pract; 2007 Sep; 13(5):444-50. PubMed ID: 17872344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
    Yoon NM; Cavaghan MK; Brunelle RL; Roach P
    Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
    Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic.
    Carrington MJ; Chan YK; Stewart S; Sjouke B; Brazilek R; Cohen N
    Intern Med J; 2014 Apr; 44(4):345-53. PubMed ID: 24877253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
    Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Lee LJ; Fonseca V
    Endocr Pract; 2012; 18(5):700-11. PubMed ID: 22982784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
    Schernthaner G; Rosas-Guzmán J; Dotta F; Guerci B; Simó R; Festa A; Kiljański J; Zhou M; Gallwitz B
    Diabetes Obes Metab; 2015 Jul; 17(7):689-98. PubMed ID: 25846577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
    Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
    Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.
    Balena R; Hensley IE; Miller S; Barnett AH
    Diabetes Obes Metab; 2013 Jun; 15(6):485-502. PubMed ID: 23061470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials.
    Busch RS; Ruggles J; Han J; Hardy E
    Int J Clin Pract; 2017 Dec; 71(12):. PubMed ID: 29044860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
    Abdul-Ghani M; Migahid O; Megahed A; Adams J; Triplitt C; DeFronzo RA; Zirie M; Jayyousi A
    Diabetes Care; 2017 Mar; 40(3):325-331. PubMed ID: 28096223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.
    Thong KY; Jose B; Sukumar N; Cull ML; Mills AP; Sathyapalan T; Shafiq W; Rigby AS; Walton C; Ryder RE;
    Diabetes Obes Metab; 2011 Aug; 13(8):703-10. PubMed ID: 21410858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
    Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
    Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
    Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
    J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
    Levin PA; Mersey JH; Zhou S; Bromberger LA
    Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
    Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
    Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide.
    Savvidou S; Karatzidou K; Tsakiri K; Gagalis A; Hytiroglou P; Goulis J
    Diabetes Res Clin Pract; 2016 Mar; 113():125-34. PubMed ID: 26803355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.